Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/79891
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cantley, M. | - |
dc.contributor.author | Rainsford, K. | - |
dc.contributor.author | Haynes, D. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Journal of Pharmacy and Pharmacology, 2013; 65(8):1214-1222 | - |
dc.identifier.issn | 0022-3573 | - |
dc.identifier.issn | 2042-7158 | - |
dc.identifier.uri | http://hdl.handle.net/2440/79891 | - |
dc.description.abstract | OBJECTIVES Osteochondrin S, a natural product derived from connective tissues and yeast, is used to treat osteoarthritis. The aim of this study was to determine the effect of Osteochondrin S on human osteoclast activity in vitro. METHODS Osteoclasts were derived from human peripheral blood mononuclear cells stimulated with macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B (RANK) ligand. Cells were treated with 23.5–587.2 ng/ml Osteochondrin S or 0.2–5 mg/ml of RNA components (synovia, placenta, intervertebral disc or cartilage). The effects on osteoclast formation and resorptive activity were assessed. Real-time polymerase chain reaction was conducted to assess the expression of key osteoclast genes. KEY FINDINGS Osteochondrin S and the individual RNA extracts resulted in a concentration-dependent inhibition of human osteoclast activity. Osteochondrin S did not affect RANK, nuclear factor of activated T cells (NFATc1), osteoclast-associated receptor or cathepsin K expression. However, there was a significant (P < 0.05) reduction in mRNA expression of calcitonin receptor. Osteochondrin S treatment also significantly increased the expression of osteoclast inhibitory factor interferon-β and, interestingly, increased the expression of tumour necrosis-α-like weak inducer of apoptosis (TWEAK). CONCLUSIONS Osteochondrin S inhibited the resorptive ability of osteoclasts. These actions are likely to occur at a late stage during osteoclast formation, downstream of NFATc1. Overall, the findings show that Osteochondrin S inhibition of osteoclast activity may be responsible for its beneficial effects on diseases such as osteoarthritis. | - |
dc.description.statementofresponsibility | Melissa D. Cantley, K. D. Rainsford and David R. Haynes | - |
dc.language.iso | en | - |
dc.publisher | Royal Pharmaceutical Soc Great Britain | - |
dc.rights | © 2013 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology | - |
dc.source.uri | http://dx.doi.org/10.1111/jphp.12088 | - |
dc.subject | Bone resorption | - |
dc.subject | in-vitro osteoclast assay | - |
dc.subject | Osteochondrin S | - |
dc.subject | RNA extracts | - |
dc.title | Effects of Osteochondrin S and select connective tissue ribonucleinate components on human osteoclasts in vitro | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/jphp.12088 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Cantley, M. [0000-0002-7188-0928] | - |
Appears in Collections: | Anatomical Sciences publications Aurora harvest 4 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.